sibo.health
Patient education on SIBO

Probiotics

The role of probiotics in SIBO is genuinely controversial, with meta-analytic data suggesting potential benefit for treatment (decontamination) but not for prevention, and a notable concern that probiotics may actually cause or worsen SIBO in some patients — particularly through D-lactic acidosis.[1][2][3]

The Paradox: Adding Bacteria to Treat Bacterial Overgrowth

The concept of using probiotics for a condition defined by excessive bacteria is inherently counterintuitive, as the ACG guideline explicitly acknowledges.[2] The proposed mechanisms by which probiotics might help include: competitive exclusion of pathogenic bacteria, production of bacteriocins (antimicrobial peptides), modulation of intestinal immune responses, possible prokinetic effects on the MMC (demonstrated in animal models), and shifts in gas-producing bacterial populations.[2][4][5]

Evidence Supporting Probiotics in SIBO

The most comprehensive meta-analysis (Zhong et al., 2017) pooled 18 studies and found:[1]

Specific Strains and Their Evidence

Probiotic Study Design Key Findings References
Saccharomyces boulardii CNCM I-745 RCT, 54 IBS-D patients with SIBO Sb + dietary advice reduced hydrogen excretion by 41% (vs. 29% with diet alone); IBS-SSS score reduced by −134 (vs. −93); diarrhea prevalence 25.9% vs. 47.6%; increased abundance of beneficial F. prausnitzii. [6]
S. boulardii + metronidazole Open-label pilot, 40 SSc patients with SIBO Combination achieved 55% SIBO eradication vs. 33% (Sb alone) vs. 25% (metronidazole alone). Sb groups had improved diarrhea, pain, and gas; metronidazole alone did not improve symptoms. [7]
Lactobacillus (Lactol) + antibiotics Double-blind RCT, 30 patients After initial antibiotic course, adding Lactol probiotic to maintenance therapy achieved 93.3% negative breath test vs. 66.7% controls (p = 0.002). Complete resolution of abdominal pain in all probiotic recipients. [8]
Bifidobacterium infantis 35624 Uncontrolled study Did not reduce hydrogen production; instead doubled the number of subjects meeting criteria for positive methane production (≥10 ppm), raising concern about shifting gas patterns rather than resolving overgrowth. [4]

The Case Against: Probiotics May Cause SIBO and D-Lactic Acidosis

The most provocative data come from the Rao et al. (2018) study, which described a syndrome of brain fogginess, gas, and bloating linked to probiotic use, SIBO, and D-lactic acidosis in patients with an intact gut.[3] Key findings:

The proposed mechanism is that certain Lactobacillus species in probiotics colonize the small intestine and ferment sugars to produce D-lactic acid, which — unlike L-lactic acid — is poorly metabolized by humans and can accumulate to cause metabolic acidosis and neurological symptoms.[3][9] This phenomenon was previously recognized only in short bowel syndrome but may occur in patients with intact gut anatomy who have impaired motility or other SIBO risk factors.[3]

Guideline Positions

The ACG (2020) does not make a formal recommendation for or against probiotics in SIBO, noting the data are mixed and that probiotics may paradoxically cause SIBO and D-lactic acidosis.[2] The AGA (2020) probiotics guideline does not specifically address SIBO as an indication.[10] A 2025 comprehensive review concluded that combining antibiotics with probiotics may increase SIBO therapy efficacy, “especially in vulnerable patients such as children and pregnant women,” but emphasized that further research is needed.[5]

Practical Considerations

Key Points

  • S. boulardii may be the most rational choice for SIBO given that it is a yeast (not a bacterium), does not produce D-lactic acid, is intrinsically resistant to antibiotics (allowing concurrent use), and has the most consistent positive data in SIBO-specific trials.[6][7][11]
  • Lactobacillus-based probiotics carry a theoretical risk of D-lactic acid production and should be used cautiously, particularly in patients with brain fogginess, slow transit, or known motility disorders.[3]
  • Probiotics appear more effective as adjunctive therapy (combined with antibiotics) than as monotherapy for SIBO eradication.[8][5]
  • Patients who develop new or worsening bloating, gas, or cognitive symptoms while taking probiotics should be evaluated for D-lactic acidosis (urinary D-lactate) and SIBO, and probiotic discontinuation should be considered.[3]
  • There is currently no evidence that probiotics prevent SIBO recurrence after successful antibiotic eradication.[1]

In summary, the probiotic-SIBO relationship is nuanced: meta-analytic data support a modest treatment benefit, but the risk of exacerbation — particularly D-lactic acidosis with Lactobacillus-containing products — is a real clinical concern. S. boulardii appears to have the most favorable risk-benefit profile in this context, though definitive RCTs are still lacking.

Next: Akkermansia muciniphila and SIBO

References

  1. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. Zhong C, Qu C, Wang B, Liang S, Zeng B. Journal of Clinical Gastroenterology. 2017;51(4):300-311. <doi:10.1097/MCG.0000000000000814>
  2. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Pimentel M, Saad RJ, Long MD, Rao SSC. The American Journal of Gastroenterology. 2020;115(2):165-178. <doi:10.14309/ajg.0000000000000501>
  3. Brain Fogginess, Gas and Bloating: A Link Between SIBO, Probiotics and Metabolic Acidosis. Rao SSC, Rehman A, Yu S, Andino NM. Clinical and Translational Gastroenterology. 2018;9(6):162. <doi:10.1038/s41424-018-0030-7>
  4. Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutrition, Prebiotics, Probiotics, and Prokinetics. Mustafa F, Noor R, Murtaza A, et al. Current Pharmaceutical Design. 2025;:CPD-EPUB-148024. <doi:10.2174/0113816128373584250407134451>
  5. A Comprehensive Review of the Usefulness of Prebiotics, Probiotics, and Postbiotics in the Diagnosis and Treatment of Small Intestine Bacterial Overgrowth. Martyniak A, Wójcicka M, Rogatko I, Piskorz T, Tomasik PJ. Microorganisms. 2025;13(1):57. <doi:10.3390/microorganisms13010057>
  6. Impact of Saccharomyces Boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study. Bustos Fernández LM, Man F, Lasa JS. Digestive Diseases (Basel, Switzerland). 2023;41(5):798-809. <doi:10.1159/000528954>
  7. Effectiveness of Saccharomyces Boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Digestive Diseases and Sciences. 2020;65(4):1134-1143. <doi:10.1007/s10620-019-05830-0>
  8. Evaluating the Efficacy of Probiotic on Treatment in Patients With Small Intestinal Bacterial Overgrowth (SIBO)–a Pilot Study. Khalighi AR, Khalighi MR, Behdani R, et al. The Indian Journal of Medical Research. 2014;140(5):604-8.
  9. Probiotics, D-Lactic Acidosis, Oxidative Stress and Strain Specificity. Vitetta L, Coulson S, Thomsen M, Nguyen T, Hall S. Gut Microbes. 2017;8(4):311-322. <doi:10.1080/19490976.2017.1279379>
  10. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Su GL, Ko CW, Bercik P, et al. Gastroenterology. 2020;159(2):697-705. <doi:10.1053/j.gastro.2020.05.059>
  11. Saccharomyces Boulardii CNCM I-745: A Non-Bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W. Current Microbiology. 2020;77(9):1987-1996. <doi:10.1007/s00284-020-02053-9>
Updated 4 May 2026